Loading clinical trials...
Loading clinical trials...
Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Conditions
Interventions
Intravitreal injection 440mcg
Intravitreal injection of sirolimus 880mcg
Locations
1
United States
Stanford University
Palo Alto, California, United States
Start Date
September 1, 2022
Primary Completion Date
September 1, 2024
Completion Date
December 1, 2024
Last Updated
October 26, 2023
NCT07218770
NCT05486468
NCT02706704
NCT06431373
NCT07262437
NCT07176130
Lead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions